Company Overview: Intelli Pharmaceutics

About the Company

Intelli Pharmaceutics
Facebook Tweeter Linkedin

Intellipharmaceutics International (NASDAQ: IPCI; TSX: I) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. In some circumstances, controlled-release drug delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug.

The company’s proprietary Hypermatrix™ technology is at the core of their controlled-release drug delivery approach. The flexibility of the Hypermatrix™ technology allows for the intelligent and efficient design of drugs through the precise control of a number of key variables. This allows the company to respond to varying drug attributes and patient requirements, producing a desired controlled-release effect in a time and cost-effective manner. Intellipharmaceutics is applying its technology to the development of both existing and new pharmaceuticals across a range of therapeutic classes.

The flexibility and the competitive advantage of the Hypermatrix™ technology allow them to focus our development activities in two niche markets:

  • Difficult-to-produce controlled-release generic drugs (ANDA regulatory path)
  • Improved current therapies through controlled release (NDA regulatory path)

Investor Toolkit

Multimedia

Company News

  • Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit

    TORONTO, July 31, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that...

  • Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®

    TORONTO, May 10, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (IPCI)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that...

  • Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”

    TORONTO, March 16, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that,...

  • Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR

    TORONTO, Feb. 24, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address